ASCIA Submissions 2023

  • ASCIA lodged a submission in response to the Food Standards Australia New Zealand (FSANZ) call for submissions on Proposal P1028 – Infant Formula.  Submission lodged 13 July 2023.

    pdfASCIA FSANZ P1028 Response July 2023258.66 KB

  • ASCIA has lodged two submissions on 23 May 2023 in support of products that are relevant to allergy and immunology, which are on the July 2023 PBAC meeting agenda.

pdfASCIA letter PBAC Avacopan 2023 05 2366.18 KB

 pdfASCIA letter PBAC Dupilumab 2023 05 2367.24 KB

  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria for thymic transplant, submitted in May 2023.
  • ASCIA has submitted two letters in support of applications for  Medical Research Future Fund (MRFF) research grants, in February and May 2023.
  • ASCIA has submitted two joint letters to the federal Health Minister, the Hon Mark Butler MP, with the National Allergy Council and Allergy & Anaphylaxis Australia regarding the feasibility of pricing for PBS listed products -  venom immunotherapy (May 2023) and medical nutrition products for cow’s milk allergy (April 2023).

Read more: ASCIA Submissions 2023

ASCIA Submissions 2022

  • ASCIA letter to Medical Services Advisory Committee (MSAC) in support for the Human Genetics Society of Australasia (HGSA) application for services provided by genetic counsellors, submitted on 7 October 2022.
    pdfASCIA supports HGSA MSAC application 20221007
  • ASCIA letter to PBAC supporting the PBS listing of PBS Nucala® (mepolizumab) for treatment of nasal polyps in chronic rhinosinusitis, submitted on 20 September 2022.
    pdfASCIA letter PBAC Nucala 2022092069.78 KB Nucala® (mepolizumab) is now subsidised by the Pharmaceutical Benefits Scheme (PBS) from 1 April 2023 as an add-on treatment for adult patients (18 years and above) with chronic rhinosinusitis with nasal polyps (CRSwNP) that is severe, eosinophilic and recurrent post-surgery.. Read more here
  • Joint letter to the federal Health Minister, the Hon Mark Butler MP, regarding pricing of medical nutrition products for cow’s milk allergy has been sent on behalf of ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Strategy, submitted on 28 July 2022.
  • Letters from ASCIA supporting research project appications to the Medical Research Future Fund (MRFF) have been submitted on 16 February, 3 March, 16 May, 24 June and 1 July 2022.
  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria about a SCID-ADA patient, in response to a request sent to ASCIA on 8 July 2022. Lodged 20 July 2022. 
  • ASCIA submitted responses to a survey on the Consultation Draft - National Medicines Policy. Lodged 2 March 2022. 
  • Letter from ASCIA in support of the application to the PBAC for PBS listing of Dupixent® (dupilumab) for treatment of severe atopic dermatitis (eczema) in children aged 6-11 years. Lodged 13 January 2022.
    pdfASCIA letter PBAC Dupilumab 2022 01 1352.73 KB
  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria about a patient with DiGeorge Syndrome and Severe Combined Immune Deficiency (SCID), in response to a request sent to ASCIA on 4 January 2022. Lodged 12 January 2022. 

Read more: ASCIA Submissions 2022

ASCIA Submissions 2021

  • ASCIA response to National Blood Authority (NBA) call for public comments on the draft Acute Transfusion Reaction Guidelines. Lodged online 2 July 2021.

Read more: ASCIA Submissions 2021

ASCIA Submissions 2020

  • ASCIA Immunodeficiency Strategy for Australia and New Zealand. Completed November 2020 and lodged as an attached to the ASCIA submission to the Parliamentary Inquiry 3 November 2020.

  • Joint letter from ASCIA, National Allergy Strategy, A&AA and CFAR to the Minister for Health (Hon Greg Hunt MP), in response to Recommendation 1 in the Report on the Parliamentay Inquiry into Allergies and Anaphylaxis. Submitted 30 June 2020. pdfJoint letter to Minister Hunt 30-06-20100.27 KB

Read more: ASCIA Submissions 2020

ASCIA Submissions 2019

  • ASCIA opening statement to the public hearing in Sydney on 19 November 2019 for the Parliamentary Inquiry into Allergies and Anaphylaxis. pdfASCIA opening statement parliamentary inquiry 19-11-19 

  • ASCIA submission to the Parliamentary Inquiry into Allergies and Anaphylaxis. Submitted 24 October 2019.
    pdfASCIA Submission Parliamentary Inquiry 24-10-19 or on the government website at Submission 153. The Inquiry report was tabled on 15 June 2020 in the Parliament of the Commonwealth of Australia.  pdfWalking the allergy tightrope1.15 MB 

  • ASCIA response to National Blood Authority (NBA) request for information regarding Berinert. Submitted 4 September 2019.
    pdfASCIA letter NBA Berinert 20190904359.77 KB

  • Feedback to Australian National Breastfeeding Strategy. Submitted 5 August 2019, further to submissions on 30 November 2018 and 18 June 2018. pdfASCIA response Australian National Breast Feeding Strategy 20190805203.32 KB This request was successful.

  • ASCIA application to the Medical Services Advisory Committee (MSAC) for a food allergen challenge Medical Benefits Schedule (MBS) item number. Submitted 18 July 2019. This submission was unsuccessful.

  •  ASCIA submission to Consultation on the Draft National Clinical Quality Registry Strategy. Submitted 20 June 2019.

  • ASCIA submission to the Food Standards Australia New Zealand (FSANZ) Review of Food Standards Code chapter 3 and 4 – Food Safety Management Requirements (Australia only). Submitted 14 June 2019.
    pdfASCIA submission FSANZ 14-06-201989.03 KB

  • ASCIA response to Pharmaceutical Benefits Advisory Committee (PBAC) request for information regarding Dupilumab. Submitted 30 May 2019.  pdfASCIA letter PBAC Dupilumab 20190530172.30 KB  This submission was unsuccessful, but Dupilumab has since been recommended by the PBAC for PBS listing. For details refer to the announcement here.

  •  ASCIA letter to National Blood Authority (NBA) regarding BloodSTAR issues. Submitted 27 May 2019. pdfASCIA letter NBA BloodSTAR 20190527 152.92 KB  The NBA has responded and will follow up on the issues raised in the ASCIA letter.

  • ASCIA response to new Medicare Benefits Schedule (MBS) Review Specialist and Consultant Physician Consultation Clinical Committee of the MBS Review Taskforce. Submitted 25 March 2019. 

  • ASCIA letter to the Royal Australasian College of Physicians (RACP) President requesting Therapeutic Goods Authority (TGA) Authorised Prescriber (AP) endorsements. Submitted 28 February 2019.  pdfASCIA letter RACP President 2019022876.31 KB  This request was unsuccessful, however the TGA has since changed the AP process.

  • ASCIA letter to the TGA regarding BICOM. Submitted 17 January 2019. pdfASCIA letter TGA BICOM 2019-01-1749.04 KB


Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia